The functional polymorphism of the hemoglobin-binding protein haptoglobin influences susceptibility to idiopathic Parkinson's disease

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 147, Issue 2, 2008, Pages 216-222

  Costa Mallen, Paola ^a,b   Checkoway, Harvey ^a   Zabeti, Aram ^a   Edenfield, Michael J ^a   Swanson, Phillip D ^a   Longstreth Jr , W T ^a   Franklin, Gary M ^a   Smith Weller, Terri ^a   Sadrzadeh, Sayed M H ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Haptoglobin; Idiopathic Parkinson's disease; Iron; Polymorphism; Smoking status

Indexed keywords

HAPTOGLOBIN;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA SCREENING; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOGLOBIN 2 2 GENE; HAPTOGLOBIN 1 1 GENE; HAPTOGLOBIN 2 1 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK; SEX DIFFERENCE; SMOKING;

EID: 40349116885     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30593     Document Type: Article

References (56)

1. Baldereschi M, Di Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E, Grigoletto F, Amaducci L, Inzitari D. 2000. Parkinson's disease and Parkinsonism in a longitudinal study: Two‐fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 55: 1358–1363.
2. Beckman L, Fröhlander N. 1990. Heterozygosity effects in studies of genetic markers and disease. Hum Hered 40: 322–329.
3. Ben‐Shachar D, Youdim MB. 1991. Intranigral iron injection induces behavioural and biochemical “parkinsonism” in rats. J Neurochem 57: 2133–2135.
4. Bowman BH, Kurosky A. 1982. Haptoglobin: The evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genet 12: 189–261, 453–454.
5. Brune JL, Yang F, Barnett DR, Bowman BH. 1984. Evolution of haptoglobin: Comparison of complementary DNA encoding Hp alpha 1S and Hp alpha 2FS. Nucleic Acids Res 12: 4531–4538.
6. Buchanan DD, Silburn PA, Prince JA, Mellick GD. 2007. Association of APOE with Parkinson disease age‐at‐onset in women. Neurosci Lett 411: 185–188.
7. Checkoway H, Franklin GM, Costa‐Mallen P, Smith‐Weller T, Dilley J, Swanson PD, Costa LG. 1998. A genetic polymorphism of MAO‐B modifies the association of cigarette smoking and Parkinson's disease. Neurology 50: 1458–1461.
8. Cid MC, Derrick SG, Hoffman GS, Auerbach R, Fauci AS, Kleinman HK. 1993. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest 91: 977–985.
9. Comings DE, MacMurray JP. 2000. Molecular heterosis: A review. Mol Genet Metab 71: 19–31.
10. De Kleijn DP, Smeets MB, Kemmeren PP, Lim SK, Van Middelaar BJ, Velema E, Schoneveld A, Pasterkamp G, Borst C. 2002. Acute‐phase protein haptoglobin is a cell migration factor involved in arterial restructuring. FASEB J 16: 1123–1125.
11. Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD. 1987. Increased nigral iron content in post‐mortem parkinsonian brain. Lancet 2: 1219–1220.
12. Earle KM. 1968. Studies in Parkinson's disease including X‐ray fluorescent spectroscopy of formalin‐fixed tissues. J Neuropathol Exp Neurol 27: 1–4.
13. Fröhlander N, Johnsson O. 1989. Haptoglobin groups in acute myocardial infarction. Hum Hered 39: 345–350.
14. Fröhlander N, Stjernberg N. 1989. Association between haptoglobin groups and hereditary predisposition for bronchial asthma. Hum Hered 39: 7–11.
15. Gerlach M, Ben‐Shachar D, Riederer P, Youdim MBH. 1994. Altered brain metabolism of iron as a cause of neurodegenerative dieases? J Neurochem 63: 793–807.
16. Götz ME, Double K, Gerlach M, Youdim MBH, Riederer P. 2004. The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 1012: 193–208.
17. Grimberg J, Nawoschik S, Belluscio L, McKee R, Turck A, Eisenberg A. 1989. A simple and efficient non‐organic procedure for the isolation of genomic DNA from blood. Nucleic Acids Res 17: 8390.
18. Halliwell B. 2001. Role of free radicals in the neurodegenerative diseases: Therapeutic implications for antioxidant treatment. Drugs Aging 18: 685–716.
19. Haugen TH, Hanley JM, Heath EC. 1981. Haptoglobin. A novel mode of biosynthesis of a liver secretory glycoprotein. J Biol Chem 256: 1055–1057.
20. Hayley S, Anisman H. 2005. Multiple mechanisms of cytokine action in neurodegenerative and psychiatric states:neurochemical and molecular substrates. Curr Pharm Des 11: 947–962.
21. Hernan MA, Takkouche B, Caamano‐Isorna F, Gestal‐Otero JJ. 2002. A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 52: 276–284.
22. Javid J. 1965. The effect of haptoglobin‐polymer size on hemoglobin binding capacity. Vox Sang 10: 320–325.
23. Kelada SN, Costa‐Mallen P, Costa LG, Smith‐Weller T, Franklin GM, Swanson PD, Longstreth WT Jr, Checkoway H. 2002. Gender difference in the interaction of smoking and monoamine oxidase B intron 13 genotype in Parkinson's disease. Neurotoxicology 23: 515–519.
24. Kliffen M, de Jong PT, Luider TM. 1995. Protein analysis of human maculae in relation to age‐related maculopathy. Lab Invest 73: 267–272.
25. Koch W, Latz W, Eichinger M, Roguin A, Levy AP, Schömig, Kastrati A. 2002. Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem 48: 1377–1382.
26. Koch W, Latz W, Eichinger M, Gschwendner C, Teige B, Schömig A, Kastrati A. 2003. Haptoglobin gene subtyping by restriction enzyme analysis. Clin Chem 49: 1937–1940.
27. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman H‐J, Law SKA, Moestrup SK. 2001. Identification of the haemoglobin scavenger receptor. Nature 409: 198–201.
28. Kurosky A, Barnett DR, Lee TH, Touchstone B, Hay RE, Arnott MS, Bowman BH, Fitch WM. 1980. Covalent structure of human haptoglobin: A serine protease homolog. Proc Natl Acad Sci U S A 77: 3388–3392.
29. Langlois MR, Delanghe JR. 1996. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 42: 1589–1600.
30. Langlois MR, Martin ME, Boelaert JR, Beaumont C, Taes YE, De Buyzere ML, Bernard DR, Neels HM, Delanghe JR. 2000. The haptoglobin 2‐2 phenotype affects serum markers of iron status in healthy males. Clin Chem 46: 1619–1625.
31. Maeda N, Yang F, Barnett DR, Bowman BH, Smithies O. 1984. Duplication within the haptoglobin Hp 2 gene. Nature 309: 131–135.
32. Mandel S, Grunblatt E, Riederer P, Amariglio N, Hirsch JJ, Rechavi G, Youdim MBH. 2005. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin‐proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC‐70. Ann N Y Acad Sci 1053: 356–375.
33. Mayeux R, Marder K, Cote LJ, Denaro J, Hemenegildo N, Mejia H, Tang MX, Lantigua R, Wilder D, Gurland B. 1995. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988–1993. Am J Epidemiol 142: 820–827.
34. McCormick DJ, Atassi MZ. 1990. Hemoglobin binding with haptoglobin: Delineation of the haptoglobin binding site on the alpha‐chain of human hemoglobin. J Protein Chem 9: 735–742.
35. McGill JR, Yang F, Baldwin WD, Brune JL, Barnett DR, Bowman BH, Moore CM. 1984. Localization of the haptoglobin alpha and beta genes (HPA and HPB) to human chromosome 16q22 by in situ hybridization. Cytogenet Cell Genet 38: 155–157.
36. Melamed‐Frank M, Lache O, Enav BI, Szafranek T, Levy NS, Ricklis RM, Levy AP. 2001. Structure‐function analysis of the antioxidant properties of haptoglobin. Blood 98: 3693–3698.
37. Mellick GD. 2006. CYP450, genetics and Parkinson's disease: Gene × environment interactions hold the key. J Neural Transm Suppl (70:) 159–165.
38. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T. 1996. Interleukin (IL)‐1 beta, IL‐2, IL‐4, IL‐6 and transforming growth factor‐alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 211: 13–16.
39. Nevo S, Sutton H. 1979. Association between response to typhoid vaccination and known genetic markers. Am J Hum Genet 20: 461–469.
40. Ostrerova‐Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, Wolozin B. 2000. The A53T α‐synuclein mutation increases iron‐dependent aggregation and toxicity. J Neurosci 20: 6048–6054.
41. Perry VH. 2004. The influence of systemic inflammation on inflammation in the brain: Implications for chronic neurodegenerative disease. Brain Behav Immun 18: 407–413.
42. Philippidis P, Mason JC, Evans BJ, Nadra I, Taylor KM, Haskard DO, Landis RC. 2004. Hemoglobin scavenger receptor CD163 mediates interleukin‐10 release and heme oxygenase‐1 synthesis: Antiinflammatory monocyte‐macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res 94: 119–126.
43. Sadrzadeh SMH, Bozorgmehr J. 2004. Haptoglobin phenotypes in health and disorders. Am J Clin Pathol 121 (Suppl): S97–S104.
44. Sadrzadeh SM, Graf E, Panter SS, Hallway PE, Eaton JW. 1984. Hemoglobin. A biologic fenton reagent. J Biol Chem 259: 14354–14356.
45. Schultze HE, Heremans JF. 1966. Nature and metabolism of extracellular proteins, Vol 1, Molecular biology of human proteins. Amsterdam: Elsevier. p 384–402.
46. Shoham S, Youdim MBH. 2000. Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. Cell Mol Biol 46: 743–760.
47. Smithies O. 1955. Zone electrophoresis in starch gels: Group variations in the serum proteins of normal human adults. Biochem J 61: 629–641.
48. Storkebaum E, Lambrechts D, Carmeliet P. 2004. VEGF: Once regarded as a specific angiogenic factor, now implicated in neuroprotection. BioEssays 26: 943–954.
49. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JW. 1999. Parkinson's disease in twins: An etiologic study. JAMA 281: 341–346.
50. Ugocsai P, Barlage S, Dada A, Schmitz G. 2006. Regulation of surface CD163 expression and cellular effects of receptor mediated hemoglobin–haptoglobin uptake on human monocytes and macrophages. Cytometry A 69: 203–205.
51. Van den Heuvel MM, Tensen CP, van As JH, Van den Berg TK, Fluitsma DM, Dijkstra CD, Dopp EA, Droste A, Van Gaalen FA, Sorg C, Hogger P, Beelen RH. 1999. Regulation of CD163 on human macrophages: Cross‐linking of CD163 induces signaling and activation. J Leukoc Biol 67: 97–103.
52. Van der Straten A, Herzog A, Cabezon T, Bollen A. 1984. Characterization of human haptoglobin cDNAs coding for alpha 2FS beta and alpha 1S beta variants. FEBS Lett 168: 103–107.
53. Van Vlierberghe H, Langlois M, Delanghe J. 2004. Haptoglobin polymorphisms and iron homeostasis in health and in disease. Clin Chim Acta 345: 35–42.
54. Yasuhara T, Shingo T, Muraoka K, Kameda M, Agari T, Ji YW, Hayase H, Hamada H, Borlongan CV, Date I. 2005. Neurorescue effects of VEGF on a rat model of Parkinson's disease. Brain Res 1053: 10–18.
55. Youdim MB, Ben‐Shachar D, Riederer P. 1991. Iron in brain function and dysfunction with emphasis on Parkinson's disease. Eur Neurol 31 (Suppl 1): S34–S40.
56. Youdim MB, Stephenson G, Ben Shachar D. 2004. Iron out iron in Parkinson's disease and other neurodegenerative diseases with iron chelators: A lesson from 6‐hydroxydopamine and iron chelators desferal and VK‐28. Ann NY Acad Sci 1012: 306–326.